Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia

Naval Daver, Aditi Shastri, Tapan Kadia, Kate Newberry, Naveen Pemmaraju, Elias Jabbour, Linghsa Zhou, Sherry Pierce, Jorge Cortes, Hagop Kantarjian, Srdan Verstovsek

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin. < 10. g/dL). Patients (n= 29; 18 RBC-transfusion dependent) received 0.5. mg pomalidomide daily in continuous 28-day cycles with prednisone given for the first 3 cycles only. Six (21%) patients responded (median response duration 11.4 months), including four who achieved RBC-transfusion-independence per the Delphi criteria and two who achieved clinical improvement (in platelets and spleen, respectively) per the International Working Group for Myelofibrosis Research and Treatment criteria. Grade 3 toxicity occurred in 1 patient (fatigue). Pomalidomide with prednisone is safe therapy with modest activity in patients with MF and anemia. ClinicalTrials.gov Identifier: NCT00946270.

Original languageEnglish (US)
Pages (from-to)1126-1129
Number of pages4
JournalLeukemia Research
Volume38
Issue number9
DOIs
StatePublished - Sep 2014

Keywords

  • Anemia
  • Myelofibrosis
  • Pomalidomide

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia'. Together they form a unique fingerprint.

  • Cite this

    Daver, N., Shastri, A., Kadia, T., Newberry, K., Pemmaraju, N., Jabbour, E., Zhou, L., Pierce, S., Cortes, J., Kantarjian, H., & Verstovsek, S. (2014). Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leukemia Research, 38(9), 1126-1129. https://doi.org/10.1016/j.leukres.2014.06.015